ArticleCureus2026
Botulinum Toxin Injection to Treat Bruxism in a Child: A Case Report and Technique Description.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Managing sleep bruxism (SB) in children remains a clinical challenge due to the limited evidence-based treatment options for muscle hyperactivity in this population. This case report describes the successful use of botulinum toxin type A (BTX-A) in managing SB in an otherwise healthy eight-year-old girl. The patient received 10 units of BTX-A in each masseter muscle, administered at two points per side using anatomical landmarks and muscle palpation to guide injection. Symptom resolution was reported as early as the day after treatment, with effects lasting approximately two months and no adverse reactions observed. This is the first known report of BTX-A being used to treat bruxism in a healthy pediatric patient. The findings suggest that botulinum toxin may be a safe and effective alternative for managing muscle hyperactivity in children. Further research is needed to establish optimal dosing protocols and long-term safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.